Key statistics
On Monday, Ultragenyx Pharmaceutical Inc (R2AR34:SAO) closed at 21.64, -7.44% below its 52-week high of 23.38, set on Mar 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 21.64 |
Low | 21.64 |
Bid | 32.40 |
Offer | 32.67 |
Previous close | 21.64 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 06 2024 20:49 BST.
More ▼
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
- Ultragenyx to Participate in Investor Conferences in September
- Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
- Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
- Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
- Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
More ▼